Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 5
Submit an article Journal homepage
152
Views
1
CrossRef citations to date
0
Altmetric
Continuing Medical Education

Optimal cardiovascular medical therapy: current guidelines and new developments

Shirley Cotty Reeda Department of Internal Medicine, Baylor Scott and White Medical Center – Temple, Temple, Texas
, DO,
Nikita Dhira Department of Internal Medicine, Baylor Scott and White Medical Center – Temple, Temple, Texas
, MD, MBA &
R. Jay Widmerb Division of Cardiology, Baylor Scott and White Medical Center – Temple, Temple, TexasCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3063-5651
, MD, PhDORCID Icon
Pages 636-642 | Received 10 Feb 2022, Accepted 06 May 2022, Published online: 16 Jun 2022

  • Gibbons RJ, Miller TD. Optimal medical therapy for known coronary artery disease: A review. JAMA Cardiol. 2017;2(9):1030–1035. doi:10.1001/jamacardio.2017.2249.
  • Smith SC, Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation. 2011;124(22):2458–2473. doi:10.1161/CIR.0b013e318235eb4d.
  • Knuuti J, Wijns W, Saraste A, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3):407–477. doi:10.1093/eurheartj/ehz425.
  • Antithrombotic Trialists’ Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7330):141–141. doi:10.1136/bmj.324.7330.141.
  • Creager MA. Results of the CAPRIE trial: Efficacy and safety of clopidogrel. Vasc Med. 1998;3(3):257–260. doi:10.1177/1358836X9800300314.
  • Collet JP, Thiele H, Barbato E, et al; ESC Scientific Document Group. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575.
  • Mehta SR, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21(24):2033–2041. doi:10.1053/euhj.2000.2474.
  • Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358(9281):527–533. doi:10.1016/s0140-6736(01)05701-4.
  • Steinhubl SR, Berger PB, Mann JT 3rd, et al; Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420. doi:10.1001/jama.288.19.2411.
  • Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166. doi:10.1056/NEJMoa1409312.
  • Bittl JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1116–1139. doi:10.1016/j.jacc.2016.03.512.
  • Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385(18):1643–1655. doi:10.1056/NEJMoa2108749.
  • Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e21–e129. doi:10.1161/CIR.0000000000001039.
  • Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664.
  • Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi:10.1056/NEJMoa1801174.
  • Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489.
  • Shavadia JS, Holmes DN, Thomas L, et al. Comparative effectiveness of β-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients. Circ Cardiovasc Qual Outcomes. 2019;12(7):e005103. doi:10.1161/CIRCOUTCOMES.118.005103.
  • Garg R, Yusuf S, Bussmann WD, et al. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273(18):1450–1456. doi:10.1001/jama.1995.03520420066040.
  • Werner C, Baumhäkel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: Current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97(7):418–431. doi:10.1007/s00392-008-0668-3.
  • Investigators O, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi:10.1056/NEJMoa0801317.
  • Pfeffer MA. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz. 1993;18(Suppl 1):430–435.
  • Sleight P. The HOPE study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2000;1(1):18–20. doi:10.3317/jraas.2000.002.
  • Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788. doi:10.1016/s0140-6736(03)14286-9.
  • Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): Design and baseline characteristics. Eur J Heart Fail. 2021;23(6):1040–1048. doi:10.1002/ejhf.2191.
  • Pitt B, Zannad F, Remme WJ, et al. Randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM199909023411001.
  • Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15(1):79–87. doi: 10.1023/a:1011119003788.
  • Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. doi:10.1056/NEJMoa1009492.
  • Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-1.
  • Bhatt DL, Miller M, Brinton EA, et al; REDUCE-IT Investigators. REDUCE-IT USA: Results from the 3146 patients randomized in the United States. Circulation. 2020;141(5):367–375. doi:10.1161/CIRCULATIONAHA.119.044440.
  • Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519. doi:10.1056/NEJMoa1912387.
  • Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. doi:10.1056/NEJMoa2110956.
  • Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117–1145. doi:10.1016/j.jacc.2020.05.037.
  • Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262–276. doi:10.1016/s0140-6736(21)00536-5.
  • Thomas RJ, Balady G, Banka G, et al. 2018 ACC/AHA clinical performance and quality measures for cardiac rehabilitation: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2018;71(16):1814–1837. doi:10.1016/j.jacc.2018.01.004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.